CXCR3/CCR5 pathways in metastatic melanoma patients treated with adoptive therapy and interleukin-2 von Bedognetti, D, Spivey, T L, Zhao, Y, Uccellini, L, Tomei, S, Dudley, M E, Ascierto, M L, De Giorgi, V, Liu, Q, Delogu, L G, Sommariva, M, Sertoli, M R, Simon, R, Wang, E, Rosenberg, S A, Marincola, F M

Volltext

IRF-1 responsiveness to IFN-γ predicts different cancer immune phenotypes von Murtas, D, Maric, D, De Giorgi, V, Reinboth, J, Worschech, A, Fetsch, P, Filie, A, Ascierto, M L, Bedognetti, D, Liu, Q, Uccellini, L, Chouchane, L, Wang, E, Marincola, F M, Tomei, S

Volltext

Translational endpoints in patients with metastatic microsatellite-stable colorectal cancer (MSS-CRC) treated with durvalumab plus monalizumab (anti-NKG2A) von Diamond, J.R., Standifer, N., Ascierto, M.L., Morehouse, C., Ghadially, H., Rodriguez Canales, J., Rebelatto, M.C., Naidoo, J., Mazzarella, L., Patel, S., Flor Oncala, M.J., Alonso Gordoa, T., Wang, D., Song, X., Jones, D.C., Li, X., Marshall, S., Abdullah, S., Jure-Kunkel, M., Hellmann, M.D.

Volltext

1194PTranslational endpoints in patients with metastatic microsatellite-stable colorectal cancer (MSS-CRC) treated with durvalumab plus monalizumab (anti-NKG2A) von Diamond, J R, Standifer, N, Ascierto, M L, Morehouse, C, Ghadially, H, Rodriguez Canales, J, Rebelatto, M C, Naidoo, J, Mazzarella, L, Patel, S, Flor Oncala, M J, Alonso Gordoa, T, Wang, D, Song, X, Jones, D C, Li, X, Marshall, S, Abdullah, S, Jure-Kunkel, M, Hellmann, M D

Volltext

BI-14 GENOMIC PROFILING OF A PREDICTIVE SIGNATURE FOR MET-TARGETED THERAPY IN GLIOBLASTOMA von Johnson, J., Ascierto, M. L., Newsome, D., Mittal, S., Kang, L., Briggs, M., Tanner, K., Berens, M. E., Marincola, F. M., Vande Woude, G. F., Xie, Q.

Volltext

IRF-1 responsiveness to IFN-[gamma] predicts different cancer immune phenotypes von Murtas, D, Maric, D, De Giorgi, V, Reinboth, J, Worschech, A, Fetsch, P, Filie, A, Ascierto, M L, Bedognetti, D, Liu, Q, Uccellini, L, Chouchane, L, Wang, E, Marincola, F M, Tomei, S

Volltext

Immunologic markers associated with favorable prognosis in breast cancer patients: Role of innate immune system von Ascierto, M. L., Kmieciak, M., Idowu, M. O., Bedognetti, D., De Maria, A., Bear, H. D., Wang, E., Marincola, F., Manjili, M.

Volltext

Perspectives in immunotherapy: meeting report from the “Immunotherapy Bridge”, Napoli, December 5th 2015 von Ascierto, Paolo A, Ascierto, Maria Libera, Formenti, Silvia, Gnjatic, Sacha, Hammers, Hans, Hirsh, Vera, Kiessling, Rolf, Melero, Ignacio, Nanda, Rita, Pawelec, Graham, Pignata, Sandro, Romero, Pedro, Speiser, Daniel E, Fox, Bernard A, Marincola, Francesco M

Volltext

LAB-EXPERIMENTAL (PRE-CLINICAL) THERAPEUTICS AND PHARMACOLOGY von Yang, F. H., Zhang, B., Zhou, D. J., Bie, L., Tom, M. W., Drummond, D. C., Nicolaides, T., Mueller, S., Banerjee, A., Park, J. W., Prados, M. D., James, D. C., Gupta, N., Hashizume, R., Strohbehn, G. W., Zhou, J., Fu, M., Patel, T. R., Piepmeier, J. M., Saltzman, W. M., Xie, Q., Johnson, J., Bradley, R., Ascierto, M. L., Kang, L., Koeman, J., Marincola, F. M., Briggs, M., Tanner, K., Vande Woude, G. F., Tanaka, S., Klofas, L. K., Wakimoto, H., Borger, D. R., Iafrate, A. J., Batchelor, T. T., Chi, A. S., Madhankumar, A. B., Slagle-Webb, B., Rizk, E., Harbaugh, K., Connor, J. R., Sarkar, G., Curran, G. L., Jenkins, R. B., Kurozumi, K., Ichikawa, T., Onishi, M., Fujii, K., Ishida, J., Shimazu, Y., Date, I., Ebsworth, K., Walters, M. J., Ertl, L. S., Wang, Y., Berahovich, R. D., Zhang, P., Powers, J. P., Liu, S.-C., Al Omran, R., Sullivan, T. J., Jaen, J. C., Brown, M., Schall, T. J., Yusuke, N., Shimizu, S., Shishido-Hara, Y., Shiokawa, Y., Nagane, M., Wang, J., Sai, K., Chen, F.-R., Chen, Z.-P., Shi, Z., Zhang, J., Zhang, K., Han, L., Chen, L., Qian, X., Zhang, A., Wang, G., Jia, Z., Pu, P., Kang, C., Kong, L.-Y., Doucette, T. A., Ferguson, S. D., Hachem, J., Yang, Y., Wei, J., Priebe, W., Fuller, G. N., Qiao, W., Rao, G., Heimberger, A. B., Chen, P.-Y., Ozawa, T., Drummond, D., Santos, R.

Volltext

Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study von Maio, M., Ascierto, P.A., Manzyuk, L., Motola-Kuba, D., Penel, N., Cassier, P.A., Bariani, G.M., De Jesus Acosta, A., Doi, T., Longo, F., Miller, W.H., Oh, D.-Y., Gottfried, M., Xu, L., Jin, F., Norwood, K., Marabelle, A.

Volltext

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma von Tawbi, Hussein A, Schadendorf, Dirk, Lipson, Evan J, Ascierto, Paolo A, Matamala, Luis, Castillo Gutiérrez, Erika, Rutkowski, Piotr, Gogas, Helen J, Lao, Christopher D, De Menezes, Juliana Janoski, Dalle, Stéphane, Arance, Ana, Grob, Jean-Jacques, Srivastava, Shivani, Abaskharoun, Mena, Hamilton, Melissa, Keidel, Sarah, Simonsen, Katy L, Sobiesk, Anne Marie, Li, Bin, Hodi, F. Stephen, Long, Georgina V

Volltext

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy von Eggermont, Alexander M.M, Chiarion-Sileni, Vanna, Grob, Jean-Jacques, Dummer, Reinhard, Wolchok, Jedd D, Schmidt, Henrik, Hamid, Omid, Robert, Caroline, Ascierto, Paolo A, Richards, Jon M, Lebbé, Céleste, Ferraresi, Virginia, Smylie, Michael, Weber, Jeffrey S, Maio, Michele, Bastholt, Lars, Mortier, Laurent, Thomas, Luc, Tahir, Saad, Hauschild, Axel, Hassel, Jessica C, Hodi, F. Stephen, Taitt, Corina, de Pril, Veerle, de Schaetzen, Gaetan, Suciu, Stefan, Testori, Alessandro

Volltext

Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma von Wolchok, Jedd D, Chiarion-Sileni, Vanna, Gonzalez, Rene, Rutkowski, Piotr, Grob, Jean-Jacques, Cowey, C. Lance, Lao, Christopher D, Wagstaff, John, Schadendorf, Dirk, Ferrucci, Pier F, Smylie, Michael, Dummer, Reinhard, Hill, Andrew, Hogg, David, Haanen, John, Carlino, Matteo S, Bechter, Oliver, Maio, Michele, Marquez-Rodas, Ivan, Guidoboni, Massimo, McArthur, Grant, Lebbé, Celeste, Ascierto, Paolo A, Long, Georgina V, Cebon, Jonathan, Sosman, Jeffrey, Postow, Michael A, Callahan, Margaret K, Walker, Dana, Rollin, Linda, Bhore, Rafia, Hodi, F. Stephen, Larkin, James

Volltext

Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial von Basset-Seguin, Nicole, Prof, Hauschild, Axel, Prof, Grob, Jean-Jacques, Prof, Kunstfeld, Rainer, Prof, Dréno, Brigitte, Prof, Mortier, Laurent, Prof, Ascierto, Paolo A, Prof, Licitra, Lisa, MD, Dutriaux, Caroline, MD, Thomas, Luc, Prof, Jouary, Thomas, MD, Meyer, Nicolas, MD, Guillot, Bernard, Prof, Dummer, Reinhard, Prof, Fife, Kate, MD, Ernst, D Scott, Prof, Williams, Sarah, MSc, Fittipaldo, Alberto, MD, Xynos, Ioannis, MD, Hansson, Johan, Prof

Volltext

Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape von Emens, Leisha A, Ascierto, Paolo A, Darcy, Phillip K, Demaria, Sandra, Eggermont, Alexander M.M, Redmond, William L, Seliger, Barbara, Marincola, Francesco M

Volltext

Binimetinib versus dacarbazine in patients with advanced NRAS -mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial von Dummer, Reinhard, Prof, Schadendorf, Dirk, Prof, Ascierto, Paolo A, MD, Arance, Ana, MD, Dutriaux, Caroline, MD, Di Giacomo, Anna Maria, MD, Rutkowski, Piotr, Prof, Del Vecchio, Michele, MD, Gutzmer, Ralf, Prof, Mandala, Mario, MD, Thomas, Luc, Prof, Demidov, Lev, Prof, Garbe, Claus, Prof, Hogg, David, MD, Liszkay, Gabriella, Prof, Queirolo, Paola, MD, Wasserman, Ernesto, MD, Ford, James, MS, Weill, Marine, MSc, Sirulnik, L Andres, MD, Jehl, Valentine, MSc, Bozón, Viviana, MD, Long, Georgina V, Prof, Flaherty, Keith, MD

Volltext

Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus von Curigliano, G., Banerjee, S., Cervantes, A., Garassino, M.C., Garrido, P., Girard, N., Haanen, J., Jordan, K., Lordick, F., Machiels, J.P., Michielin, O., Peters, S., Tabernero, J., Douillard, J.Y., Pentheroudakis, G., Addeo, A., Albiges, L., Ascierto, P.A., Banerjee, S., Barlesi, F., Caldas, C., Cardoso, F., Cervantes, A., Chaberny, I.F., Cherny, N.I., Choueiri, T.K., Chua, M.L.K., Criscitiello, C., Curigliano, G., de Azambuja, E., De Ruysscher, D., de Vries, E., Dent, R., Douillard, J.Y., D’Ugo, D., Dziadziuszko, R., Faivre-Finn, C., Felip, E., Garassino, M., Garrido, P., Girard, N., Glynne-Jones, R., Golfinopoulos, V., Haanen, J., Hamilton, E., Jänne, P.A., Jordan, K., Kanesvaran, R., Kim, S.B., Liebert, U.G., Lordick, F., Machiels, J.P., Michielin, O., Mok, T.S.K., Morgan, G., Obermannova, R., Park, K., Passaro, A., Pentheroudakis, G., Peters, S., Reck, M., Salazar Soler, R., Scotté, F., Senan, S., Sessa, C., Smyth, E., Soo, R., Soria, J.C., Spicer, J., Strasser, F., Tabernero, J., Tan, D.S.W., Trapani, D., Van Cutsem, E., van Halteren, H., van Schil, P.E., Veronesi, G., Yang, J.

Volltext

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma von Larkin, James, Chiarion-Sileni, Vanna, Gonzalez, Rene, Grob, Jean Jacques, Cowey, C. Lance, Lao, Christopher D, Schadendorf, Dirk, Dummer, Reinhard, Smylie, Michael, Rutkowski, Piotr, Ferrucci, Pier F, Hill, Andrew, Wagstaff, John, Carlino, Matteo S, Haanen, John B, Maio, Michele, Marquez-Rodas, Ivan, McArthur, Grant A, Ascierto, Paolo A, Long, Georgina V, Callahan, Margaret K, Postow, Michael A, Grossmann, Kenneth, Sznol, Mario, Dreno, Brigitte, Bastholt, Lars, Yang, Arvin, Rollin, Linda M, Horak, Christine, Hodi, F. Stephen, Wolchok, Jedd D

Volltext

Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma von Owen, C.N., Bai, X., Quah, T., Lo, S.N., Allayous, C., Callaghan, S., Martínez-Vila, C., Wallace, R., Bhave, P., Reijers, I.L.M., Thompson, N., Vanella, V., Gerard, C.L., Aspeslagh, S., Labianca, A., Khattak, A., Mandala, M., Xu, W., Neyns, B., Michielin, O., Blank, C.U., Welsh, S.J., Haydon, A., Sandhu, S., Mangana, J., McQuade, J.L., Ascierto, P.A., Zimmer, L., Johnson, D.B., Arance, A., Lorigan, P., Lebbé, C., Carlino, M.S., Sullivan, R.J., Long, G.V., Menzies, A.M.

Volltext

MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study von Ascierto, Paolo A, MD, Schadendorf, Dirk, Prof, Berking, Carola, Prof, Agarwala, Sanjiv S, Prof, van Herpen, Carla ML, MD, Queirolo, Paola, MD, Blank, Christian U, MD, Hauschild, Axel, Prof, Beck, J Thaddeus, MD, St-Pierre, Annie, PhD, Niazi, Faiz, MPharm, Wandel, Simon, PhD, Peters, Malte, MD, Zubel, Angela, MD, Dummer, Reinhard, Prof

Volltext